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The following is a report of the proceedings of the Nocturia Think Tank sessions of the annual International Consulta-
tion on Incontinence-Research Society, which took place June 13–15, 2011 in Bristol, UK. The report is organized into
sections pertaining to the main topics of discussions having occurred at that meeting, centering on the relationship of
nocturnal polyuria (NP) and nocturia but also synthesizing more current evidence advancing our knowledge of the
diagnosis and management of nocturia. This article is not meant to be a comprehensive review on the subject of noctu-
ria, a number of which are available in the recent literature. All authors were physically present during, or in a prelim-
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CLASSIFICATION OF NOCTURIA
Evaluation of nocturia begins with a history and physical
examination which focuses on aspects such as sleep quality,
urinary complaints, ﬂuid intake, cardiac problems, type and
timing of various medications, prior lower urinary tract sur-
gery and other comorbidities that might account for excessive
nocturnal urine output, detrusor overactivity or abnormal
bladder sensory function. A key instrument in the evaluation
and diagnosis of nocturia is the frequency volume chart (FVC),
in which patients record the volume and timing of daytime
and nighttime voids for 1–3 days. Based upon analysis of the
24-hr FVC, the patient may be categorized as having any of
the following: (1) NP; (2) low bladder capacity (nocturnal and/
or 24 hr); (3) mixed (a combination of NP and low global or
nocturnal bladder capacity [NBC]); and (4) polyuria. Each cate-
gory is associated with a differential of several medical condi-
tions which may be investigated further and treated as part or
all of the condition associated with nocturia (see Table I). Un-
fortunately, despite appropriate evaluation, in many patients
clearly identiﬁable remediable conditions are not found, in
which case nocturia may be idiopathic (‘‘primary nocturia’’),
thereby requiring a therapeutic approach on an empiric basis.
Multiple FVCs afford the physician an opportunity to review
day-to-day differences in toileting habits and to discuss with
the patient how the details of daily intake, activity, and bath-
room availability relate to changes in FVC data. If average val-
ues of multiple FVCs are used consistently, the useful details
of daily diary data differences may be obscured.
Nocturnal Polyuria
Normally, urine is produced in an age-dependent circadian
pattern. In young people (age <25 years) the mean nocturnal
polyuria index (NPi, nocturnal urine volume [NUV]/24-hr
urine volume) ¼ 0.14 compared to that of older people
(age >65 years) whose mean NPi ¼ 0.34.1 NUV is the sum of
voided volumes during the hours of sleep which includes the
volume of the ﬁrst morning void assuming the latter takes
place promptly upon arising. Accordingly, the International
Continence Society has deﬁned NP to exist when 24-hr urine
production is within normal limits and NPi is greater than
0.33.2 Several other deﬁnitions of NP have been used. They
include NUV greater than 6.4 ml/kg, nocturnal urine output
>0.9 ml/min (54 ml/hr) or higher3 and >90 ml/hr.4 Thus, for
an ‘‘average’’ 70 kg person who sleeps about 8 hr, the upper
limit of urine excreted during the hours of sleep is expected
to be from 450 to 720 ml, depending upon the cut point used.
Diagnosis of NP leads to a differential diagnosis including
excessive evening ﬂuid intake (behavioral factors), third
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spacing (e.g., due to venous disease of the legs), cardiac dys-
function and obstructive sleep apnea.
Decreased Bladder Capacity
The two types of nocturia due to diminished bladder capaci-
ty are (1) global (24 hr) decrease in bladder capacity as
expressed by low maximum voided volume and (2) decreased
nocturnal bladder capacity. In both conditions nocturnal
urinary volume exceeds bladder capacity and the patient is
awakened by the need to void because the bladder does not
hold enough. Urological causes of low nocturnal and global
bladder capacity include infravesical obstruction, idiopathic
nocturnal detrusor overactivity, neurogenic voiding dysfunc-
tion, cystitis, bladder calculi, ureteral calculi and neoplasms
of the bladder, prostate, or urethra. Urological evaluation for
etiology of diminished bladder capacity includes cystoscopic
and urodynamic techniques for diagnosing these disorders.
Timing of medication intake should be carefully sought dur-
ing the history-taking interview. Medications which pharma-
cologically decrease bladder capacity may cause nocturia if
taken just prior to retiring. While there is clinical evidence
that beta blocking drugs exacerbate involuntary bladder con-
tractions in patients with neurological disease, these agents
seem to have less effect on normal bladders.5 On the other
hand, beta blockers were not found to be associated with an
increased prevalence of nocturia in the Boston Area Commu-
nity Health Survey.6 While urological causes for low bladder
capacity may be found, it is often difﬁcult to distinguish
resulting global from nocturnal decreases in bladder capacity.
To some extent, therefore, treatment of low bladder capacity
may beneﬁt patients during the day and not night, or vice-
versa. Follow-up of such therapy is necessary in order to mea-
sure the beneﬁt as speciﬁcally regards nocturia.
Mixed Nocturia
Many patients with nocturia have a combination of NP and
low nocturnal bladder capacity. Diminished NBC appears to
play a greater role in the pathogenesis of nocturia in younger
patients, whereas in older patients NP assumes relatively
greater importance.7 In view of emerging evidence of the mul-
tifactorial etiology of nocturia in individual patients,8 the
‘‘mixed’’ category would seem to be particularly relevant, in
that treatment yielding clinically satisfying outcomes will
likely require institution of multiple incremental additive
therapies.
Polyuria
Polyuria is deﬁned as a 24-hr urine output greater than
40 ml/kg, causing daytime urinary frequency and nocturia as-
sociated with a general increase in urine output, outstripping
even normal bladder capacity. Inappropriate excretion of
water in cases of polyuria leads to polydipsia in order to main-
tain homeostasis. Causes of global polyuria are uncontrolled
diabetes mellitus, diabetes insipidus (DI), and primary poly-
dipsia. DI is a disorder of water balance. Central DI is caused
by deﬁcient synthesis of antidiuretic hormone (ADH) second-
ary to loss of neurosecretory neurons in the hypothalamus or
posterior hypophysis; nephrogenic DI is due to an inability of
the kidneys to respond to ADH. When polyuria is demonstrat-
ed using the voiding diary, a water deprivation test may be
performed to distinguish between DI and primary polydipsia
which may be either dipsogenic or psychogenic.9 Dipsogenic
polydipsia is associated with a history of central neurological
abnormality such as prior brain trauma, radiation, or surgery.
Psychogenic polydipsia is a long-term behavioral or psychiat-
ric disorder.
On balance it would seem that a diary-based classiﬁcation
scheme such as that presented above naturally should lead to
rational, cause-speciﬁc therapy of nocturia. However, treat-
ment of a condition which addresses each underlying patho-
physiologic factor is not always practical. By way of analogy,
even though erectile dysfunction, like nocturia, has multiple
potential underlying causes such as hypogonadism, large
vessel disease, small vessel disease, venous insufﬁciency and
psychogenic factors, treatment usually follows an algorithm
independent of etiology, and based more upon safest and least
invasive treatment ﬁrst followed by more invasive, higher
risk treatment further on. Veriﬁcation of a cause-speciﬁc treat-
ment algorithm for nocturia mandates a considerable clinical
research commitment in the future.
NOCTURNAL POLYURIA IN OLDER MEN AS
DEFINED BY THE KRIMPEN STUDY
According to the most recent ICS deﬁnition, NP is present
when an increased proportion of the 24-hr output occurs at
night.10 The ICS standardization report on terminology further
states that the normal range of nocturnal urine production
(NUP) differs with age and normal ranges remain to be de-
ﬁned. Therefore, NP is present when greater than 20% (young
adults) to 33% (over 65 years) is produced at night. However,
these suggested deﬁnitions of NP, which refer to a day/night
ratio in urine production were not based on normal distribu-
tions and were not properly validated.11
Clearly, FVCs are excellent tools to evaluate NUP in an epi-
demiological setting.4 In the Krimpen study, urine production
for each hour of the day was computed according to the meth-
od described by Van Mastrigt and Eijskoot12: urine production
was assumed constant between two voidings and hourly
urine production was estimated as the volume of each mictu-
rition divided by the number of hours that passed since
the previous micturition. NUP per hour was estimated as the
mean between 1 am and 6 am, because 90% of the men
were asleep in this period.
TABLE I. Diary-Based Categorization of Nocturia and Respective Underly-
ing Medical Conditions
Nocturia category Underlying medical conditions
Nocturnal polyuria Congestive heart failure
Diabetes mellitus
Obstructive sleep apnea
Peripheral edema
Excessive nighttime fluid intake
Idiopathic (‘‘primary’’)
Diminished global or low
nocturnal bladder capacity
Bladder outlet obstruction
Nocturnal detrusor overactivity
Neurogenic voiding dysfunction
Cancer of bladder, prostate, or urethra
Pelvic floor dysfunction
Anxiety disorders
Pharmacologic agents (e.g.,
cyclophosphamide, propranolol)
Bladder, ureteral calculi
Polyuria Uncontrolled diabetes mellitus
Diabetes insipidus
Primary polydipsia
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Reference Values for Nocturnal Urine Production and
Determinants of Nocturnal Urine Production in Older Men
At baseline, a 3-day frequency-volume chart was completed
by 95% of the participants. Mean NUP was 60.6 (SD 32.6) ml/
hr in men aged 50–78 years.4 Linear regression analyses on
NUP was performed to identify possible determinants. In mul-
tivariate analyses, the signiﬁcant determinants of increased
NUP are: age, smoking, and 24-hr polyuria.
The mean NUP in ml/hr for the age strata 50–54, 55–59, 60–
64, 65–69, and 70–78 years were 53.4, 54.2, 58.3, 62.8, and
66.6 ml/hr, respectively. Mean NUP is signiﬁcantly higher,
that is, 100.9 ml/hr in men with 24-hr polyuria (>2,500 ml
per 24 hr). Men who smoke have a slightly lower NUP (mean
47.5 ml/hr).
A cut-off value for increased NUP was deﬁned using logistic
regression analysis. The best model was the one with the
highest percentage of explained variance, and was derived
from ROC curves. Based on these analyses we suggest that
a NUP exceeding 90 ml/hr is abnormal. However, about
one-third of the men with ‘‘increased’’ NUP according to this
cut-off value also have 24-hr polyuria.4
Epidemiology of Nocturnal Polyuria in Older Men
To study the epidemiology of NP, urine production for each
hour of the day was determined as described above. Two
different deﬁnitions of NP were used:
(1) Nocturnal urine volume >33% of 24-hr total urine volume
(abbreviated as ‘‘NUP33%/24 hr’’).
(2) Nocturnal urine production >90 ml/hr (abbreviated as
‘‘NUP90’’).
The percentage of men with NP was determined for the dif-
ferent age strata using these deﬁnitions.
Age Group Specific Prevalence of Nocturnal Polyuria
at Baseline and Follow-Up
The prevalence of NUP33%/24 hr and NUP90 in communi-
ty-dwelling men between 50 and 78 years clearly increases
with age.4 The prevalence rate of men with NUP33%/24 hr, is
high (>40%) for all age strata and rising from 41.8% (95%
CI: 36.2–47.4) between 50 and 54 years, to 56.9% (95%
CI: 49.5–64.3) between 70 and 78 years. For both deﬁnitions, a
clear relation with advancing age was shown. The lowest
prevalence was shown for the deﬁnition NUP90, rising from
12.1% (95% CI: 8.4–15.9) in men between 50 and 54 years, to
23.6% (95% CI: 17.2–29.9) in men between 70 and 78 years.13
The longitudinal evolution of the prevalence rates in the
subsequent study rounds only showed slight variations over
time for all deﬁnitions. The largest increase after 6.5 years of
follow-up (from 47.5% to 62.5%) was shown for NUP33%/
24 hr in men from the baseline age stratum of 60–64 years.13
SLEEP APNEA AND NOCTURIA: UPDATE
Sleep disturbances such as insomnia, obstructive sleep
apnea, restless legs syndrome and periodic leg movements,
snoring and parasomnias, for example, sleep walking have
been implicated in the etiology of nocturia. The precise rela-
tionship between sleep apnea and nocturia has not been
thoroughly studied but it seems to be related to increased
pressure in the right side of the heart. Obstructive sleep apnea
is caused by a blockage of the airway, when the soft tissue in
the rear of the throat collapses and closes during sleep. This
sets-off a series of physiological processes: oxygen supply
decreases, carbon dioxide levels increase and the blood
becomes more acidic resulting in bradycardia and pulmonary
vasoconstriction.14 The patient then wakes up to breathe by
which time the heart rate increases and the heart senses a
false signal of ﬂuid overload which results in the secretion of
atrial natriuretic peptide (ANP) to get rid of sodium and water,
resulting in nocturia.15,16 The worse the sleep apnea, the
worse the nocturia.17 Treatment of sleep apnea with continu-
ous positive airway pressure seems to reduce nocturia in these
patients.18
In a cluster analysis of patients from the EpiLUTS study,
sleep apnea was in the same cluster as nocturia in women but
not in men.19 However, as the number of nocturia episodes
increased, so did the frequency of sleep apnea in both men
and women (see Table II). Nocturia is an independent predic-
tor for severe obstructive sleep apnea in patients with ische-
mic stroke20 and seems to be a predictor of sleep apnea just
like snoring.8,21 Although the association between nocturia
and sleep apnea is established from small clinical trials and
epidemiological data we still do not know the exact relation-
ship between the two and whether sleep apnea causes noctu-
ria or vice versa. Sleep apnea also seems to be related to
overactive bladder (OAB) syndrome,22,23 benign prostatic
enlargement,24 and metabolic syndrome.25
We need research into this area of nocturia as well as look-
ing at simple treatments such as weight loss for sleep apnea
and its relationship to nocturia.
SIMPLIFIED VERSUS EXTENDED ALGORITHM FOR
EVALUATION AND TREATMENT OF NOCTURIA
Treatment algorithms for management of nocturia have
proved difﬁcult to develop, though several possible examples
have been proposed and published. A simple algorithm suit-
able for primary care would be highly desirable, in view of the
high prevalence of the condition. Such an algorithm needs to
be simple and self-evident, communicating the importance of
evaluating ﬂuid intake and output, so the physician makes
the distinction between lower urinary tract, renal and pre-
renal causes of nocturia. Thus the physician would be directed
appropriately for initial investigation and management,
including triggers to indicate whether a signiﬁcant medical
comorbidity may be present.26 Such an algorithm should also
TABLE II. Frequency of Sleep Apnea in Nocturia Subgroups
Sleep apnea or sleep disorder
Number of nocturia episodes
0 1 2 3 P-value
Men N ¼ 4,318, 433 (10.0%) N ¼ 5,768, 742 (12.9%) N ¼ 2,196, 375 (17.1%) N ¼ 1,825, 372 (20.4%) <0.0001
Women N ¼ 3,834, 251 (6.6%) N ¼ 6,649, 574 (8.6%) N ¼ 2,954, 362 (12.2%) N ¼ 2,373, 455 (19.2%) <0.0001
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include steps for realistic appraisal of treatment response and
appropriate follow up.
By its nature, nocturia is a multifactorial and complex inter-
play of body systems, and some of comorbidities may be med-
ically signiﬁcant.8 Inevitably therefore, a simple algorithm
will not necessarily yield a high proportion of patients
achieving symptomatic response they would perceive to be
adequate. Accordingly, a more complex algorithm, able to
discern the numerous systems inﬂuencing nocturnal urine
output, and their relative contribution, is going to be neces-
sary for refractory bothersome nocturia in the secondary care
setting. Such an algorithm needs to make allowance for broad
assessment across multiple body systems, with the sensitivity
to ascertain more speciﬁc testing according to phenotypic trig-
gers, and then detailed evaluation and management which
may fall into a specialist bracket. Much of the specialty work
will fall outside the typical training experience of most urolo-
gists or urogynecologists, for whom endocrinology, autonomic
physiology, and renal medicine are not core training topics.
Accordingly, such an algorithm must reﬂect some key points:
the multidisciplinary nature of the team-working essential
for comprehensive investigation and treatment success;
selective testing based on predictive criteria identiﬁed in
history and examination;
identifying simple screening measures that can be done by
secondary care physicians—so as to avoid interdisciplinary
referral with no resulting beneﬁt;
avoidance of treatment where satisfactory symptomatic
response cannot be anticipated.
Whilst many algorithms have been proposed, none has
been drawn up with an interdisciplinary dialogue sufﬁcient
to meet these needs. This would be an ambitious and chal-
lenging process, as it would require a substantial array of
specialists; urology, urogynecology, renal medicine, internal
medicine, neurology, geriatrics, cardiovascular medicine, sleep
medicine, respiratory medicine, etc. Nonetheless, the beneﬁts
to patients and the medical profession that would result if
such a consensus could be achieved render the development
of a combination of simple primary care and extended second-
ary care algorithms a clinical priority and a research priority.
RECOMMENDATION FOR BEST CURRENT NOCTURIA-SPECIFIC
SLEEP QUALITY QUESTIONNAIRES
Nocturia is bothersome for a remarkable proportion of the
general population and is associated with impaired quality of
life (QoL).27 The assessment of the impact of these adverse
effects has evolved from generic to speciﬁc with the evolution
of instruments speciﬁcally designed and validated for this
purpose. Generally, condition-speciﬁc measures are more
responsive to small changes. On the other hand, global meas-
ures provided by a generic QoL instrument can be more robust
and give an indication of the impact on everyday activities
and overall well-being compared with narrower information
from a condition-speciﬁc instrument (see Table III).28
The Nocturia-speciﬁc Quality of Life Questionnaire (N-QOL)
is a condition-speciﬁc questionnaire developed for men with
nocturia.29 The N-QOL is a 13-item instrument, available in 17
languages, and takes approximately 5 min to complete.30
After initial evaluation in small focus groups and psychomet-
ric validation, reproducibility and validity of the total score
and subscale scores have been demonstrated. Subscales that
have been identiﬁed within this score include sleep/energy
and bother/concern, both of which have high loading factors
for nocturia impact. N-QOL scores were shown to correlate
with sleep quality (measured by the Pittsburgh Sleep Quality
Index (PSQI))31 and energy/vitality and social functioning
(measured by the SF-36 Health Survey (SF-36)). The N-QOL has
been shown to demonstrate differences in scores between
individuals experiencing one, two, and three voids/night
indicating discriminant validity. In a Taiwanese study,32 the
validity of N-QOL was also shown among women. However,
responsiveness to change and clinical signiﬁcance of change
of scores remains to be assessed in an intervention study. The
N-QOL represents the ﬁrst questionnaire to have been speciﬁ-
cally developed to assess nocturia impact on QoL. Another
instrument speciﬁcally validated for assessment of the impact
of nocturia is the Nocturia, Nocturnal Enuresis and Sleep-
Interruption Questionnaire (NNES-Q).33 It has been validated
in a mailed questionnaire study among elderly. NNES-Q
includes 12 questions on nocturia, nocturnal enuresis, sleep-
interruptions, treatment and physical function. NNES-Q
remains to be validated in a younger population and in clini-
cal practice.
Attempts have been made to correlate scales assessing low-
er urinary tract symptoms with impact of nocturia. Coyne
et al.34 found that the Urinary Sensation Scale (USS) discrimi-
nated nocturia in women but not in men. Van Dijk et al.
assessed 1,000 Dutch men and women using the Bristol
Female Lower Urinary Tract Symptoms Questionnaire (BF-
LUTS), the Sleep Wake Experience List (SWEL35), and the
RAND-36 scales.36 They noted nocturia effects mediated by
sleep problems having statistically signiﬁcant effects on BF-
LUTS subscales, SWEL, and RAND-36 scores.37,38 Similarly, the
BPH Impact Index,39 ICS QoL,40 BPH survey,41 Veterans Affairs
Questionnaire,42 and the Olmstead County Questionnaire43
have been used to capture the impact of nocturia in men. The
Incontinence Impact Questionnaire (IIQ44) and King’s Health
TABLE III. Questionnaires Employed in Study of Nocturia
Questionnaire (see text) Use in genders Comments
ICIQ-N-QoL Both Nocturia-specific
NNES-Q Both Nocturia-specific; validated in elderly only
DAN-PSS Both Assesses not only nocturia severity but also bother; validated in men; nocturia questions seem
not gender-specific
AUA-SI/IPSS Both Assesses nocturia severity
BF-LUTS Both Assesses nocturia severity; validated in women; nocturia question seems not gender-specific
ICS QoL Men 6 questions as part of the ICS ‘‘BPH’’ questionnaire
BPH Impact Index/Symptom
Problem Index
Men Does not assess nocturia but questions on health feeling with and social implications of LUTS
EuroQoL-5D, SF-36, RAND-36, 15D Both Generic health-related quality of life instruments
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Questionnaire45 have been used in women for assessment of
this symptom.46 Among both genders, occurrence and bother
of nocturia was assessed by the Danish Prostatic Symptom
Score (DAN-PSS) in a Finnish population-based study.8 Most
respondents reported bother from nocturia with two voids/
night and moderate bother only with three or more nocturia
episodes.
Relation of nocturia with health related QoL has also been
assessed by the generic 15D instrument (including 15 dimen-
sions of QoL).8,47 In a Finnish population-based study,27 report-
ing two voids/night was related with clinically importantly
impaired QoL whereas a single episode was not. This ﬁnding
is consistent with a US female urology clinic study and a com-
munity-based Taiwanese study48 which proposed that clini-
cally signiﬁcant nocturia is 2 voids per night. In the US
study,49 the American Urologic Association Symptom Index
(AUA-SI50) and the Symptom Problem Index (SPI) was used,
whereas the N-QOL29 was used in the Taiwanese study.
Kobelt et al., in a Swedish population, assessed the relation-
ship between two generic QoL instruments (the EQ-5D (Euro-
Qol51) and the SF-3652—speciﬁcally the vitality and energy
domains) and the Short quantitative Work Productivity and
Activity Impairment (WPAI53) in a group of nocturic patients
compared with controls. Nocturia resulted in signiﬁcantly
lower vitality and utility as aspects of quality-of-life.54 Fur-
thermore, increasing nocturia was related with impaired
work productivity.
We recommend use of the N-QOL for baseline and follow-up
assessments of nocturia therapy until other clinically validat-
ed options become available. However, generic QoL instru-
ments and other possible effects of nocturia, such as
diminished work productivity, could also be included in
outcome assessment.
SUMMARY OF MEDICATIONS CAUSING INCREASED URINE
OUTPUT (AS A SIDE EFFECT) AND THEIR MECHANISMS
Knowledge of patient medication intake including over-
the-counter medications and vitamins is of signiﬁcant value
in the evaluation of patients with nocturia. Diuresis is an
expected outcome in patients on diuretic therapy and may
contribute to global or NP; however, there is a long list of med-
ications that contribute to the condition due to the secondary
renal effect of the medication on water or salt balance.
Medications can cause polyuria by increasing water intake
(polydipsia), by interfering in renal ability to concentrate
urine (DI), by causing venous stasis, or via unknown mecha-
nisms (see Table IV).
It is important to review water homeostasis to understand
some of the mechanistic pathways through which certain
medications contribute to polyuria. Excessive ﬁltration of a
poorly reabsorbed solute such as glucose, mannitol, or urea
can depress reabsorption of NaCl and water in the proximal
tubule and lead to enhanced excretion in the urine. Poorly
controlled diabetes mellitus with glycosuria is the commonest
cause of solute diuresis, leading to volume depletion and
serum hypertonicity. Common iatrogenic solute diuresis
occurs from mannitol administration, radiocontrast media,
and high-protein feedings (enterally or parenterally), leading
to increased urea production and excretion.55
Formation of large volumes of dilute urine is usually due to
polydipsic states or DI. Primary polydipsia can result from
habit, psychiatric disorders, neurologic lesions, or medications.
During deliberate polydipsia, extracellular ﬂuid volume is
normal or expanded and plasma vasopressin (AVP) levels are
reduced because serum osmolality tends to be near the lower
limits of normal. Drugs that produce dry mouth (phenothia-
zine and anticholinergics) or any peripheral disorder causing
pathologic elevation of renin and/or angiotensin can cause
primary polydipsia. An important cause of NP is pedal edema,
which results in NP via mobilization of ﬂuid when the patient
retires to the reclining position during sleep. NP is associated
with venous insufﬁciency, congestive heart failure, and
medications. Examples of the latter include non-steroidal anti-
inﬂammatory drugs (via suppression of AVP-inhibiting
prostaglandin E2) and thiazolidinedione antidiabetic agents.
Arginine vasopressin (AVP) is one of the most important
hormones in water homeostasis. It binds to the type 2 vaso-
pressin receptor (V2R) on the basolateral membrane of princi-
pal cells in the collecting ducts and connecting tubules,
activates adenylyl cyclase (AC), increases intracellular cyclic
adenosine monophosphatase (cAMP), and stimulates protein
kinase A (PKA) activity. The resulting increase in cellular
cAMP and PKA activity triggers an increased rate of insertion
of water channel-containing vesicles (aquaporin 2) into the
apical membrane that increases permeability of the apical
membrane.56 For maximum concentration of urine, large
amounts of urea must be deposited in the interstitium of the
inner medulla. V2-receptor activation also increases urea
permeability by 400% in the terminal portions of the inner
medullary collecting duct. V2 receptors increase urea perme-
ability by activating an AVP-regulated urea transporter most
likely by PKA-induced phosphorylation.57 In addition to the
above, V2-receptor activation also increases Na
þ transport in
the thick ascending limb and collecting duct of the nephron.
DI can be caused by either insufﬁcient AVP (central DI) or
the lack of AVP effect (nephrogenic DI). Inhibitors of vasopres-
sin secretion (central DI) include ethanol, phenytoin, low doses
of morphine, glucocorticoids, ﬂuphenazine, haloperidol, prom-
ethazine, oxilorphan, and butorphanol. Lithium is the most
common cause of drug-induced nephrogenic DI. As many as
10–20% of patients on chronic lithium therapy develop some
degree of NDI. Lithium is known to reduce V2-receptor-mediat-
ed stimulation of AC and produces a dramatic (95%) reduction
in renal aquaporin (AQP2) levels in animals. Other causes
of NDI include antibiotics like demeclocycline, cisplatin, me-
thoxyﬂurane, amphotericin B, foscarnet, ifosfamide, clozapine.
The antibiotic demeclocycline attenuates the antidiuretic
TABLE IV. Summary of Medications Causing Increased Urine Output
Medication
Mechanism of increased
urine output
Ethanol, morphine, glucocorticoids,
fluphenazine, haloperidol,
promethazine, oxilorphan,
butorphanol
Inhibition of endogenous
vasopressin secretion
Lithium, demeclocycline, cisplatinum,
methoxyflurane, amphotericin B,
foscarnet, ifosfamide, clozapine
Reduced renal
aquaporin-2 levels
Conivaptan, tolvaptan V2-receptor antagonist
Calcium channel blockers Direct blocking of
proximal tubular sodium
reabsorption or increased
atrial natriuretic
peptide levels
Carbonic anhydrase inhibitors Reduced sodium and
bicarbonate reabsorption
in proximal tubule
Excessive vitamins A and D; thiazides Hypercalcemia proximate
consequence, secondary
renal concentrating defect
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effects of vasopressin, probably owing to decreased accumula-
tion and action of cAMP.58
Lack of AVP-stimulated activation of the V2 receptors in the
connecting tubules is the basis of AVP receptor antagonists’
induction of polyuria. Conivaptan and tolvaptan (V2-receptor
antagonists) are developed to treat hyponatremia in euvole-
mic/hypervolumic patients.58
Many calcium-channel blockers produce polyuria via a
direct blocking of the reabsorption of sodium in the proximal
renal tubule59 or alteration in ANP plasma levels.60
Carbonic anhydrase inhibitors (methazolamide and acet-
azolamide) act upon carbonic anhydrase, located at the lumi-
nal border of cells of the proximal tubule.61 When the enzyme
is inhibited there is an increase in urine volume, and a change
to an alkaline pH, with subsequent decrease in the excretion
of both titratable acid and ammonia.62
Drugs causing hypercalcemia can produce polyuria. Chronic
hypercalcemia leads to a defect in concentrating ability that
may induce polyuria and polydipsia in up to 20% of patients.
The mechanism is incompletely understood, but downregula-
tion of AQP2 water channels, and calcium deposition in
the medulla with secondary tubulointerstitial injury and
impaired generation of the interstitial osmotic gradient may
play important roles. Hypervitaminosis A, hypervitaminosis
D, and thiazide diuretics can result in hypercalcemia.
PHARMACOTHERAPY OF NOCTURNAL
POLYURIA WITH ANTIDIURETICS
Before using pharmacotherapy to treat NP, relevant comor-
bidities (DI, heart failure, and renal insufﬁciency) should be
addressed.
Further, non-invasive treatments should be considered
(evening ﬂuid, caffeine and alcohol reduction as well as stock-
ings, warm sleep environment and socks).
If this approach is insufﬁcient, antidiuretic treatment with
desmopressin is indicated.63 Desmopressin, internationally
registered as a treatment for NP, is a synthetic analogue of
AVP, the endogenous ADH. Desmopressin is a selective vaso-
pressin-2 receptor agonist which has its effect predominantly
on antidiuresis. It has neither vasoconstrictive nor oxytocic
effects, unlike its native congener.
The antidiuretic treatment of NP has been reviewed in
2010.64 It was concluded that desmopressin has a signiﬁcant
beneﬁcial clinical and statistical effect on nocturnal voiding
frequency, sleep, bother, QoL, and productivity.
Recently the results of a randomized, single blinded, placebo
controlled trial with 136 men with benign prostatic hyperpla-
sia (BPH) older than 65 years of age was published.65 All men
suffered from nocturia, NP and had an International Prostate
Symptom Score of 14 or higher. It was concluded that low
dose oral desmopressin (0.1 mg) is an effective and well-
tolerated treatment for NP among such patients. A clinical
response (decrease of 2 or more voids per night) was achieved
in 35 patients (61.4%) receiving desmopressin and in 8 place-
bo-treated patients (13.8%) (P < 0.001). It was found that
long-term desmopressin therapy gradually decreases serum
sodium and might induce hyponatremia even in patients
with normal baseline serum sodium.65 Kang et al.66 analyzed
the short term effect of desmopressin. They compared an
adult group (20 patients <64 years of age) with an elderly
cohort (14 patients >65 years of age) having NP. Desmopres-
sin appeared to be well tolerated and effective after a treat-
ment period of 2 weeks in both groups. Only two patients
(from the elderly cohort) developed hyponatremia, which
resolved after discontinuation of therapy.
Lee et al.67 performed a dose-titration study followed by a
treatment period of 4 weeks with the individual optimum
oral dose. They enrolled 103 patients with mixed nocturia.
Ninety-four patients completed the dose-titration study and
90 patients (95.7%) completed the treatment-period (one
withdrawal because of neck-stiffness and three withdrawals
because of loss to follow-up). The optimum doses were as fol-
lows: 44% (n ¼ 41) of patients received 0.1 mg oral desmo-
pressin, 33% (n ¼ 31) received 0.2 mg of desmopressin, and
23% (n ¼ 22) received 0.4 mg of desmopressin. In 72% of the
patients (n ¼ 68) (95% CI: 0.63–0.81) (P < 0.001), the mean
number of nocturnal voids decreased signiﬁcantly from 3.20
to 1.34 after the 4-week treatment with desmopressin. The
number of patients that reported a good night sleep increased
signiﬁcantly from 19.8% to 78.7% after 4 weeks of desmopres-
sin treatment (P < 0.001).
Overall it can be concluded that desmopressin is an effec-
tive treatment option for NP and nocturia.68,69
DESMOPRESSIN: GENDER DIFFERENCES
Whilst there is considerable evidence to suggest that in-
creasing age and female gender are risk factors for developing
hyponatremia whilst taking desmopressin therapy70 until
recently there have been few data assessing gender differen-
ces in relation to antidiuretic response.
Previous studies have demonstrated the diurnal variation in
ADH secretion in 69 healthy volunteers and have shown a
twofold higher concentration in male subjects when com-
pared to female subjects71 although since urine osmolality
were similar in both groups72 this suggests that women have
a higher renal sensitivity when compared to men. Further-
more there is some evidence to suggest that estrogens lower
the plasma osmotic threshold for antidiuretic hormone73 and
consequently increase renal sensitivity.
The concept of a possible gender difference is supported by
genetic research which has shown signiﬁcantly more V2
receptor (V2R) mRNA in female rats when compared to male
rats and a greater sensitivity to V2R agonist administration.74
Further work has demonstrated that mutations in the AVPR2
gene, located on the X chromosome may cause polyuric, poly-
dipsic, and antidiuretic disorders. Clinically these appear to be
less severe in the female phenotype when compared to the
male phenotype probably due to female carriers ‘‘escaping’’ X
inactivation, thereby causing phenotypic variability.75 In
addition the AVPR2 gene has a high probability of escaping X
inactivation76 and hence may be responsible for gender differ-
ences in renal V2R expression.
The gender differences in renal sensitivity and response
have also been demonstrated in clinical studies investigating
the use of desmopressin in the management of nocturia. Two
double blind placebo controlled studies, the Noctupus studies,
have been reported in 144 women77 and 151 men.78 Although
neither of these studies were speciﬁcally designed to investi-
gate for gender differences in response to therapy further
analysis of the results suggests that women experienced
greater efﬁcacy when compared to men. The primary end-
point of both studies was the number of subjects with a 50%
reduction in nocturnal voids. This was achieved in 46% of
women as compared to 34% of men. In addition, women were
found to have a 78% increase in mean time to ﬁrst nocturnal
void as compared to a 59% increase in men.
Whilst evidence from the Noctupus studies would certainly
suggest a gender difference in the efﬁcacy of desmopressin
more direct evidence is provided by a recently completed
North American trial of desmopressin orally disintegrating
Nocturia Think Tank 335
Neurourology and Urodynamics DOI 10.1002/nau
tablets (Minirin Melt).79 In the ﬁrst double blind phase of the
study subjects were randomized to placebo or oral desmopres-
sin (10, 25, 50, or 100 mg), for 1 month, and were then invited
to continue in a 12-month open label extension study. Overall
799 subjects were recruited with 710 (89%) completing the
double blind phase and 665 continued into the open label
extension study. The co-primary endpoints were the mean
change in nocturnal voids from baseline and the proportion of
subjects with >33% reduction in mean nocturnal voids. A
dose response effect was seen during the study with a signiﬁ-
cant difference in efﬁcacy between the 50 and 100 mg doses
when compared to placebo. The 25 mg dose was shown to
have a clinical effect, although not signiﬁcantly greater than
placebo, whilst the 10 mg dose was sub-therapeutic. However
a subsequent post hoc analysis has shown a signiﬁcantly
greater decrease in NUV in women at the lower doses of 10
and 25 mg when compared to men. Equally the ED50 was
found to be lower in women when compared to men (16.1 mg
vs. 43.2 mg) suggesting signiﬁcantly higher sensitivity to des-
mopressin in women. This ﬁnding is also supported by a ﬁve-
fold higher risk of hyponatremia, deﬁned as a sodium level
below 130 mmol/L, in women over 50 years old at the 50 mg
dose when compared to men. Consequently, whilst 50–100 mg
is an efﬁcacious dose in men these ﬁndings would suggest
that 25 mg is equally efﬁcacious in women and in addition
there were no observed instances of hyponatremia at this low
dose level.80
In conclusion, the emerging evidence would appear to sug-
gest that women have an increased sensitivity to desmopres-
sin and may therefore achieve a similar clinical effect with a
lower therapeutic dose. In clinical practice this should allow
physicians treating women with nocturia to minimize the risk
of hyponatremia whist still achieving a meaningful clinical
effect.
ANTIMUSCARINICS AS THERAPY FOR NOCTURICS
Despite commonly reported statistically signiﬁcant results,
nocturia has not shown a clinical signiﬁcant response to tradi-
tional therapies for OAB, including antimuscarinics.81 Simple
logic would predict this, using as a model the ‘‘typical’’ patient
with OAB who has 12 voids a day with 1–4 episodes of arising
from sleep to void and 50% of the voids occurring with urgen-
cy. An effective antimuscarinic will reduce the episodes of ur-
gency by 50% with a drug/placebo ratio of approximately 2:1.
For reduction in nocturia, this would amount to, assuming
that the only effect of the antimuscarinic would be on the
urgency-associated episodes, a reduction in nocturia from 4 to
3, 3 to 2.25, and 2 to 1.5. Clearly the beneﬁt would be most
appreciated by those more severely afﬂicted with nocturia, if
the theory is correct. The following citations prove the point.
These are not meant to select any particular drug(s) for criti-
cism, merely to support the initial statement.
Brubaker and Fitzgerald82 pooled data from four trials
(3 months each) which included men and women with noctu-
ria treated with solifenacin 5 and 10 mg, and placebo. Results
were categorized as ‘‘all’’ and those with and without NP. The
only statistically signiﬁcant difference from placebo was in
the no NP group. Reduction in nocturic episodes in the placebo
group was 1.70–1.27; for both S5 and S10, 1.66–1.05. Rackley
et al.83 reported on a population of OAB patients with an aver-
age of 2.5 episodes or more of nocturia, treated with a night-
time dose of tolterodine LA 4 mg. Results were characterized
into total nocturia episodes, those not due to OAB (no urgen-
cy), those due to OAB and to ‘‘severe OAB’’ (severe urgency).
The median percentage reductions in nocturia were not
statistically signiﬁcant versus placebo for the total and non-
OAB nocturia events but were for OAB and severe OAB events.
Respectively, the later reductions were 30 versus 22% (base-
line 2.5 for drug, 2.4 for placebo) and 59 versus 43% (baseline
1.03 and 0.96). Although a ‘‘signal’’ exists, the clinical signiﬁ-
cance is, at best, arguable. Zinner et al.84 compared the results
with trospium 20 mg bid to placebo in a 12-week trial. The
decreases in nocturia amounted to 2.10–1.63 for drug, 2.00–
1.71 for placebo, statistically signiﬁcant for the drug. Rudy
et al.85 used the same design with almost identical results:
2.10–1.63 for drug, 2.00–1.71 for placebo. Studies looking at
the effects of fesoterodine on nocturia failed to show statisti-
cally or clinically signiﬁcant changes.86–89 In a head to head
comparison of tolterodine and fesoterodine, Kaplan et al.90
reported a 33.3% reduction in nocturnal micturitions at
12 weeks for fesoterodine (baseline 2.2), 33.3% for tolterodine
(baseline 2.3), and 27.3% for placebo (baseline 2.1). The fesoter-
odine reduction was statistically signiﬁcant versus placebo
(P < 0.05), but the calculated reduction is hardly clinically
relevant.
Although those patients with severe OAB may beneﬁt from
antimuscarinic therapy, this is the only group that would be
expected to have any positive result with respect to nocturia,
but this effect is minimal. At best in such patients, this could
be additive in a multimodal approach to the management of
nocturia.
EVIDENCE FOR TREATMENT OF NOCTURIA VIA COMPRESSION
DEVICES, TIMED DIURETICS, AND BEHAVIORAL TREATMENT
NP can be directly addressed using compression stockings
to reduce peripheral edema, timed diuretics to induce urine
output prior to sleep, and by changing patterns of ﬂuid intake
through behavioral treatments such as ﬂuid management.
Because these treatments are non-speciﬁc, there is wide
general recommendation for their use, but little direct evi-
dence for the effectiveness of these treatments.91
General Advice
Nighttime ﬂuid intake and coffee intake, practices providers
commonly target in patients with nocturia, were not associat-
ed with nocturia in a study of elderly patients.92 Fluid manip-
ulation will more likely affect symptoms than will caffeine
changes.93 Intervention trials manipulating 24-hr total ﬂuid
intake (though neither ﬂuid type nor timing) with ﬂuid intake
reduction (by 25%) showed a small, statistically signiﬁcant
reduction (0.1 episode less on average) in nocturia.94 Individu-
als had difﬁculty maintaining prescribed alterations of either
50% greater or less ﬂuid intake, and will not likely be a mean-
ingful intervention.
Compression Devices
Peripheral third-spacing of ﬂuids is common in middle-aged
and elderly patients; with elevation of the legs, these ﬂuids
are mobilized and can result in signiﬁcant nocturia. The
volume of accumulated extracellular ﬂuid, speciﬁcally in the
lower extremities, correlates with NUV.95 However, studies of
compression devices with nocturia as a measurable outcome
have not been performed. In an open ‘‘label’’ study, there was
a large treatment effect from combined therapy which includ-
ed the use of lower extremity stockings in 45% of 55 men who
had >2 episodes of nocturia associated with peripheral
edema, recruited from a primary care clinic.96 There was no
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control group in this study and compliance with wearing the
stockings was not assessed.
Timed Diuretics
Diuretics given at bedtime would dramatically exacerbate
the problem of nocturia; diuretics given late in the afternoon
so that their effect is complete by bedtime can improve noctu-
ria. Reynard et al.97 asked middle-aged men with LUTS to keep
a FVC, and in those with NP, 40 mg of furosemide 6 hr before
usual bed time resulted in a signiﬁcant reduction (net reduc-
tion of 0.5 fewer episodes in treatment versus control) in
night-time frequency and percentage voided NUV. Staggered
furosemide and desmopressin might provide a rational treat-
ment for nocturia in the elderly98 although diuretic-induced
sodium loss may predispose such patients to hyponatremia
with the combination.
Behavioral treatment: Fluid management is widely used to
manage OAB, especially where a frequency/volume diary has
recorded high ﬂuid intake and urine output in individuals. In
a large multicenter study of women with OAB, Zimmern and
coworkers found that general ﬂuid instructions contributed to
reduction of UUI symptoms in women taking anticholinergic
medications, with a decrease in the number of voids per
24 hr. Speciﬁc nighttime volumes were not reported.99 Two
trials have shown that combined behavioral therapy, includ-
ing ﬂuid timing instructions, pelvic ﬂoor muscle exercises and
urge-suppression strategies, reduces nocturia to a greater ex-
tent than oxybutynin. The ﬁrst study was a post hoc analysis
of a treatment trial in women with urge urinary incontinence
(behavior vs. bladder relaxant vs. placebo). Here, combined be-
havioral therapy resulted in greater mean changes in nocturia
(0.5) when compared to either individually titrated oxybuty-
nin IR (0.3) or to placebo (0.0).100 Similar results were later
demonstrated in men whose 24-hr urinary frequency did not
resolve with an alpha-blocker therapy run-in. For nocturia
reductions, behavioral therapy and pelvic ﬂoor muscle exer-
cises added to alpha-blocker therapy resulted in greater
changes in nocturia when compared to individually titrated
oxybutynin XL (mean reduction ¼ 0.70 vs. 0.32 episodes/
night; P ¼ 0.05).101 The clinical beneﬁt of this statistically bor-
derline improvement in nocturia, as is the case with many of
its treatments, is likely to be unappreciated by most patients.
CONCLUSIONS
Advances in diagnosis and management of nocturia were
discussed amongst a large cross section of international
experts during the 2011 Bristol ICI-RS meeting. At the present
time it appears that NP is the greater of the multiple treatable
substrates comprising the genesis of this extremely common,
bothersome and potentially morbid condition.
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